Page 1 of 220
NAMS MENOPAUSE CERTIFICATION ACTUAL
EXAM WITH 300 QUESTIONS AND CORRECT
DETAILED SOLUTIONS JUST RELEASED THIS
YEAR
NAMS MENOPAUSE CERTIFICATION EXAM
300 RANDOMIZED SCENARIO-BASED QUESTIONS
With Answers and Summarized Rationales
Question 1
A 52-year-old woman reports 3 months of irregular periods followed by a 45-day interval
without menses, and is now experiencing hot flashes and night sweats. Which stage of the
menopause transition is most consistent with her presentation?
A) Early reproductive (-3b)
B) Late reproductive (-2)
C) Early menopausal transition (-1a)
D) Late menopausal transition (-1b)
E) Postmenopause (+1a)
1
SUCCESS!
,Page 2 of 220
Answer: D
The STRAW+10 system defines late menopausal transition (-1b) by the occurrence of
amenorrhea of 60 days or more, accompanied by vasomotor symptoms and elevated FSH levels.
Question 2
A 48-year-old woman with a history of breast cancer diagnosed 3 years ago presents with
severe hot flashes affecting her sleep and quality of life. She is currently taking tamoxifen.
Which treatment option is most appropriate?
A) Systemic estrogen therapy
B) Venlafaxine
C) Progestin-only therapy
D) Testosterone therapy
E) Tibolone
Answer: B
Venlafaxine is a non-hormonal option effective for vasomotor symptoms in breast cancer
survivors. Systemic estrogen is contraindicated in breast cancer survivors, and tamoxifen
interacts with certain hormonal therapies.
2
SUCCESS!
,Page 3 of 220
Question 3
A 55-year-old postmenopausal woman presents with vaginal dryness, dyspareunia, and urinary
urgency. Examination reveals pale, friable vaginal mucosa with loss of rugae. What is the most
appropriate first-line treatment?
A) Systemic hormone therapy
B) Vaginal estrogen cream
C) Oral ospemifene
D) Vaginal moisturizers
E) Systemic antibiotics
Answer: D
Vaginal moisturizers and lubricants are recommended as first-line treatment for genitourinary
syndrome of menopause, with vaginal estrogen reserved for persistent symptoms.
Question 4
A 62-year-old woman with osteoporosis and no personal history of breast cancer asks about the
best treatment to reduce fracture risk. Her DEXA T-score is -2.8 at the femoral neck. What is the
3
SUCCESS!
, Page 4 of 220
most appropriate initial pharmacologic therapy?
A) Raloxifene
B) Alendronate
C) Calcitonin
D) Estrogen therapy
E) Calcium supplementation alone
Answer: B
Bisphosphonates such as alendronate are first-line therapy for osteoporosis in postmenopausal
women with a T-score ≤ -2.5, reducing vertebral and hip fracture risk significantly.
Question 5
A 50-year-old perimenopausal woman reports heavy menstrual bleeding, fatigue, and iron
deficiency anemia. Pelvic ultrasound reveals a 3 cm submucosal fibroid. What is the most
appropriate management approach?
A) Hysterectomy
B) Levonorgestrel-releasing intrauterine device
C) Oral contraceptives
4
SUCCESS!
NAMS MENOPAUSE CERTIFICATION ACTUAL
EXAM WITH 300 QUESTIONS AND CORRECT
DETAILED SOLUTIONS JUST RELEASED THIS
YEAR
NAMS MENOPAUSE CERTIFICATION EXAM
300 RANDOMIZED SCENARIO-BASED QUESTIONS
With Answers and Summarized Rationales
Question 1
A 52-year-old woman reports 3 months of irregular periods followed by a 45-day interval
without menses, and is now experiencing hot flashes and night sweats. Which stage of the
menopause transition is most consistent with her presentation?
A) Early reproductive (-3b)
B) Late reproductive (-2)
C) Early menopausal transition (-1a)
D) Late menopausal transition (-1b)
E) Postmenopause (+1a)
1
SUCCESS!
,Page 2 of 220
Answer: D
The STRAW+10 system defines late menopausal transition (-1b) by the occurrence of
amenorrhea of 60 days or more, accompanied by vasomotor symptoms and elevated FSH levels.
Question 2
A 48-year-old woman with a history of breast cancer diagnosed 3 years ago presents with
severe hot flashes affecting her sleep and quality of life. She is currently taking tamoxifen.
Which treatment option is most appropriate?
A) Systemic estrogen therapy
B) Venlafaxine
C) Progestin-only therapy
D) Testosterone therapy
E) Tibolone
Answer: B
Venlafaxine is a non-hormonal option effective for vasomotor symptoms in breast cancer
survivors. Systemic estrogen is contraindicated in breast cancer survivors, and tamoxifen
interacts with certain hormonal therapies.
2
SUCCESS!
,Page 3 of 220
Question 3
A 55-year-old postmenopausal woman presents with vaginal dryness, dyspareunia, and urinary
urgency. Examination reveals pale, friable vaginal mucosa with loss of rugae. What is the most
appropriate first-line treatment?
A) Systemic hormone therapy
B) Vaginal estrogen cream
C) Oral ospemifene
D) Vaginal moisturizers
E) Systemic antibiotics
Answer: D
Vaginal moisturizers and lubricants are recommended as first-line treatment for genitourinary
syndrome of menopause, with vaginal estrogen reserved for persistent symptoms.
Question 4
A 62-year-old woman with osteoporosis and no personal history of breast cancer asks about the
best treatment to reduce fracture risk. Her DEXA T-score is -2.8 at the femoral neck. What is the
3
SUCCESS!
, Page 4 of 220
most appropriate initial pharmacologic therapy?
A) Raloxifene
B) Alendronate
C) Calcitonin
D) Estrogen therapy
E) Calcium supplementation alone
Answer: B
Bisphosphonates such as alendronate are first-line therapy for osteoporosis in postmenopausal
women with a T-score ≤ -2.5, reducing vertebral and hip fracture risk significantly.
Question 5
A 50-year-old perimenopausal woman reports heavy menstrual bleeding, fatigue, and iron
deficiency anemia. Pelvic ultrasound reveals a 3 cm submucosal fibroid. What is the most
appropriate management approach?
A) Hysterectomy
B) Levonorgestrel-releasing intrauterine device
C) Oral contraceptives
4
SUCCESS!
